Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
O-1821
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
O-1821 (Cannabidiorcol) is a phytocannabinoid analog structurally similar to cannabidiol (CBD), naturally found in Cannabis plants. It is a cannabidiol variant with a shortened side chain (pentyl replaced by methyl). The compound is structurally related to O-1918, a selective antagonist of abnormal cannabidiol that operates through CB1/CB2/nitric oxide-independent mechanisms. O-1821 is primarily used as an analytical reference standard in cannabis research. The compound's mechanism involves endothelium-dependent vasodilation and modulation of phosphorylation pathways including p42/44 mitogen-activated protein kinase and protein kinase B/Akt.
- Other names
- CannabidiorcolCBDOCBD-C1CBD-C-1CBD-C 1
02
Targets
GPR18 (G protein-coupled receptor 18)
Beyond the preview
Go deeper on O-1821.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on O-1821.